New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA

In the last few years, much new information has been generated on the pathophysiology, possible therapeutic targets, and pharmacologic treatment of overactive bladder (OAB). Antimuscarinic drugs are still first-line pharmacologic treatment for OAB and often have good initial response rates, but adve...

Descripción completa

Detalles Bibliográficos
Autor principal: Andersson, Karl-Erik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3634323/
https://www.ncbi.nlm.nih.gov/pubmed/23637536
http://dx.doi.org/10.2147/TCRM.S33052

Ejemplares similares